Jada D. Williams

Jada D. Williams

Auto-generated profile, based on publicly available information

Jada D. Williams

Department of Physiology, University of Tennessee Health Science Center, Memphis, TN

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LRLuis O. Romero
Luis O. Romero
MBManisha Bade
Manisha Bade
LELaila Elsherif
Laila Elsherif
JWJada D. Williams
Jada D. Williams
XKXiangmei Kong
Xiangmei Kong
VVValeria Vásquez
Valeria Vásquez
Sickle cell disease (SCD), an inherited blood disorder caused by a mutation in the β-globin gene, is characterized by sickle erythrocytes that are prone to hemolysis, leading to anemia and vaso-occlusion crises. In sickle erythrocytes, hemoglobin aggregation is followed by altered cation permeability and subsequent dehydration. Interventions that restore cation permeability can decrease hemolysis and ameliorate the symptoms associated with SCD. PIEZO1 is a nonselective mechanosensitive cation channel that regulates erythrocyte volume. Gain-of-function (GOF) mutations in PIEZO1 cause hemolytic anemia by increasing cation permeability, leading to erythrocyte dehydration in humans and mice. Although PIEZO1 plays a key role in erythrocyte homeostasis, its role in SCD remains unknown. Here, we demonstrate that the function of the PIEZO1 channel is upregulated in sickle erythrocytes of humans and mice, and this enhancement can be restored through a dietary intervention. We found that PIEZO1 activity in sickle erythrocytes resembles that of the GOF mutation causing hemolytic anemia. A diet enriched in the ω -3 fatty acid eicosapentaenoic (EPA) acid decreases PIEZO1 activity in sickle erythrocytes, attenuates hemolysis, and reduces hypoxia-induced sickling. Furthermore, EPA reduces inflammatory markers. We propose that PIEZO1 contributes to the increase in nonselective cationic conductance (i.e., Psickle), which leads to dehydration downstream of hemoglobin polymerization. Our results suggest that reducing PIEZO1 function represents a promising therapeutic strategy to reestablishing normal cation permeability in SCD.

19 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LRLuis O. Romero
Luis O. Romero
MBManisha Bade
Manisha Bade
LELaila Elsherif
Laila Elsherif
JWJada D. Williams
Jada D. Williams
XKXiangmei Kong
Xiangmei Kong
VVValeria Vásquez
Valeria Vásquez
Sickle cell disease (SCD), an inherited blood disorder caused by a mutation in the β-globin gene, is characterized by sickle erythrocytes that are prone to hemolysis, causing anemia and vaso-occlusion crises. In sickle erythrocytes, hemoglobin aggregation is followed by altered cation permeability and subsequent dehydration. Interventions to restore cation permeability can decrease hemolysis and ameliorate the symptoms associated with SCD. PIEZO1 is a non-selective mechanosensitive cation channel that regulates erythrocyte volume. Gain-of-function (GOF) mutations in PIEZO1 cause hemolytic anemia by increasing cation permeability, leading to erythrocyte dehydration in humans and mice. Although PIEZO1 plays a key role in erythrocyte homeostasis, its role in SCD remains unknown. Here, we demonstrate that the function of the PIEZO1 channel is upregulated in sickle erythrocytes of humans and mice, and this enhancement can be restored through a dietary intervention. We found that PIEZO1 function in sickle erythrocytes resembles that of the GOF mutation causing hemolytic anemia. A diet enriched in the ω -3 fatty acid eicosapentaenoic (EPA) acid decreases PIEZO1 function in sickle erythrocytes and hemolysis in a mouse model of SCD. Furthermore, EPA decreases hemolysis and reduces inflammatory markers. We propose that PIEZO1 contributes to the increase in nonselective cationic conductance (i.e., Psickle), which leads to dehydration downstream of hemoglobin polymerization. Our results suggest that reducing PIEZO1 function is a promising therapeutic approach to reestablishing normal cation permeability in SCD.

2 July 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
OFOlufunke O. Falayi
Olufunke O. Falayi
JWJada D. Williams
Jada D. Williams
RKRavi Kumar
Ravi Kumar
OAOlufunke Omolola Arishe
Olufunke Omolola Arishe
JAJeremiah M. Afolabi
Jeremiah M. Afolabi
Adebowale AdebiyiAdebowale Adebiyi
Adebowale Adebiyi
Sickle cell disease (SCD) is characterized by chronic intravascular hemolysis and depletion of the heme scavenger hemopexin (HPX), generating a high-heme milieu that may increase susceptibility to inflammatory organ injury. Sepsis is a leading cause of acute kidney injury (AKI), yet the contribution of hemolysis-derived free heme to polymicrobial sepsis-associated AKI in SCD remains poorly defined. Using humanized SCD mice, we tested whether augmenting heme clearance via HPX mitigates septic AKI. Low-grade cecal ligation and puncture induced exaggerated systemic inflammation, elevated circulating heme and ferritin, and marked reductions in glomerular filtration rate (GFR) in sickling (hemoglobin SS [HbSS]) mice compared with nonsickling (HbAA) control mice. Septic SS mice also exhibited enhanced renal nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation, increased oxidative stress, and tubular injury, consistent with heme-driven inflammatory and cytotoxic signaling. Acute administration of purified human HPX reduced circulating heme and ferritin, attenuated cytokine responses, and preserved GFR, indicating that restoration of heme buffering in SCD interrupts kidney injury pathways during septic stress. To achieve sustained heme control, we restored HPX expression using liver-directed delivery of adeno-associated virus serotype 8 (AAV8). AAV8-HPX restored hepatic HPX, reduced basal and sepsis-induced plasma heme levels, conferred protection against kidney dysfunction and tubular stress, and improved survival without evidence of hepatotoxicity. Collectively, these findings identify free heme as a central mediator linking hemolysis to sepsis-associated AKI in SCD, and establish that HPX augmentation via protein replacement or gene therapy is a mechanistically targeted, potentially translatable therapeutic strategy to mitigate heme-driven tissue injury and improve outcomes in SCD-associated sepsis.


4 September 2026 in Advances in Redox Research
Verified
Journal Article
Open access
JWJada D. Williams
Jada D. Williams
OMOlugbenga S. Michael
Olugbenga S. Michael
OAOlalekan S. Adebiyi
Olalekan S. Adebiyi
FPFrank Park
Frank Park
Adebowale AdebiyiAdebowale Adebiyi
Adebowale Adebiyi